To date, SKYRIZI® (risankizumab) has been listed for the treatment of UC on the public drug formularies in Quebec (Médicament d'exception)6, Nova Scotia (Exception Drug Status)7, Non-Insured Health Benefits (NIHB) (Limited Use)8, Prince Edward Island (Special Authorization)9, Alberta (Special Authorization)2 and Ontario (Exceptional Access Program)1. We are continuing our efforts to make sure SKYRIZI® (risankizumab) is accessible for patients with UC and listed on the public drug formularies across the country in a timely manner.

Canada's Drug Agency (CDA-AMC) has recommended SKYRIZI® (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met last November4.

"Ulcerative colitis is a complex, chronic condition that can significantly impact patients' quality of life. Expanding access to new treatment options is an important step toward more personalized care" said Dr. John Marshall, Professor of Medicine and Director of the Division of Gastroenterology at McMaster University. "Having additional therapies available allows us as health care professionals to better tailor treatment to individual patient needs, align with patient preferences, and improve long-term outcomes".

"Improving access to new treatment options is a critical step for people living with ulcerative colitis. This listing helps reduce barriers to advanced therapies and gives patients and their care teams more timely options to manage a complex, lifelong disease," said Josh Berman, President and CEO of Crohn's and Colitis Canada.

"This is a testament to AbbVie's and the Health Institutions' continuous progress in expanding patient access to innovative medicines for inflammatory bowel disease" said Arima Ventin, Director, Market Access and Government Affairs, AbbVie Canada. "AbbVie in Canada is dedicated to working alongside provinces to provide access to treatment options that could have an impact on patients' lives".